rabeprazole has been researched along with Curling Ulcer in 51 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Curling Ulcer: Acute stress DUODENAL ULCER, usually observed in patients with extensive third-degree burns.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this multicenter, randomized, double-blind, double-dummy, positive-drug parallel-controlled, phase III study, Chinese patients with duodenal ulcers were randomized 1:1 to receive rabeprazole 10 mg + anaprazole placebo or rabeprazole placebo + anaprazole 20 mg once daily for 4 weeks." | 9.51 | Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study. ( Ding, J; Du, Y; Fan, H; Huang, C; Li, Z; Lyu, N; Pan, X; Pan, Z; Shi, Z; Sun, H; Wang, Q; Zhang, L; Zhu, H, 2022) |
| "Ilaprazole is a kind of benzimidazole proton-pump inhibitor, which was confirmed efficacious and safe in treatment of duodenal ulcer (DU)." | 9.30 | Ilaprazole Compared With Rabeprazole in the Treatment of Duodenal Ulcer: A Randomized, Double-blind, Active-controlled, Multicenter Study. ( Fan, L; Haitang, H; Jielai, X; Ling, W; Xianghong, Q; Ying, H, 2019) |
| "To investigate the effect of Helicobacter pylori eradication on endothelin-1 (ET-1) and nitric oxide (NO) in duodenal ulcer (DU) patients." | 9.11 | Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication. ( Chang, FY; Chen, CY; Lee, SD; Lu, CL; Lu, RH; Luo, JC, 2005) |
| "Rabeprazole (10 mg/day) has excellent therapeutic effect on the symptoms of duodenal ulcer patients." | 9.10 | [The short term effect of rabeprazol versus omeprazole on symptom relief of duodenal ulcer]. ( Lin, S, 2002) |
| "It was to determine the efficacy of rabeprazole at 20 and 40 mg in addition to amoxicillin and clarithromycin in the treatment of active Helicobacter pylori-positive duodenal ulcers compared with omeprazole 40 mg." | 9.10 | Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Scalia, A; Terminella, C, 2002) |
| "This randomized, double-blind, multicentre study, conducted at 25 European sites, compared the efficacy and tolerability of rabeprazole and omeprazole in patients with active duodenal ulcers." | 9.09 | Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. ( Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1999) |
| "The primary purpose of this study was to compare the efficacy and tolerability of rabeprazole versus ranitidine in the treatment of patients with active duodenal ulcer disease." | 9.09 | Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study. ( Breiter, JR; Humphries, TJ; Riff, D, 2000) |
| "Rabeprazole, a new proton pump inhibitor, was studied in patients with acid-peptic-related diseases (duodenal ulcer, gastric ulcer, GERD) in three placebo-controlled, double-blind, randomized clinical trials." | 9.08 | Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. ( Bassion, S; Cloud, ML; Enas, N; Humphries, TJ, 1998) |
| "This article presents considerations currently under discussion about the probability of HP participation in the ulcer causation as well as information about Rabeprazole efficiency for anti-helicobacter therapy of non-complicated duodenal ulcer (as a result of 7-day anti-helicobacter therapy, the healing of duodenal bulbs was recorded in 82." | 8.82 | [Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)]. ( Vasil'ev, IuB, 2004) |
| "In this multicenter, randomized, double-blind, double-dummy, positive-drug parallel-controlled, phase III study, Chinese patients with duodenal ulcers were randomized 1:1 to receive rabeprazole 10 mg + anaprazole placebo or rabeprazole placebo + anaprazole 20 mg once daily for 4 weeks." | 5.51 | Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study. ( Ding, J; Du, Y; Fan, H; Huang, C; Li, Z; Lyu, N; Pan, X; Pan, Z; Shi, Z; Sun, H; Wang, Q; Zhang, L; Zhu, H, 2022) |
| "Ilaprazole is a kind of benzimidazole proton-pump inhibitor, which was confirmed efficacious and safe in treatment of duodenal ulcer (DU)." | 5.30 | Ilaprazole Compared With Rabeprazole in the Treatment of Duodenal Ulcer: A Randomized, Double-blind, Active-controlled, Multicenter Study. ( Fan, L; Haitang, H; Jielai, X; Ling, W; Xianghong, Q; Ying, H, 2019) |
| "To investigate the effect of Helicobacter pylori eradication on endothelin-1 (ET-1) and nitric oxide (NO) in duodenal ulcer (DU) patients." | 5.11 | Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication. ( Chang, FY; Chen, CY; Lee, SD; Lu, CL; Lu, RH; Luo, JC, 2005) |
| "Rabeprazole (10 mg/day) has excellent therapeutic effect on the symptoms of duodenal ulcer patients." | 5.10 | [The short term effect of rabeprazol versus omeprazole on symptom relief of duodenal ulcer]. ( Lin, S, 2002) |
| "It was to determine the efficacy of rabeprazole at 20 and 40 mg in addition to amoxicillin and clarithromycin in the treatment of active Helicobacter pylori-positive duodenal ulcers compared with omeprazole 40 mg." | 5.10 | Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Scalia, A; Terminella, C, 2002) |
| "This randomized, double-blind, multicentre study, conducted at 25 European sites, compared the efficacy and tolerability of rabeprazole and omeprazole in patients with active duodenal ulcers." | 5.09 | Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. ( Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1999) |
| "The primary purpose of this study was to compare the efficacy and tolerability of rabeprazole versus ranitidine in the treatment of patients with active duodenal ulcer disease." | 5.09 | Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study. ( Breiter, JR; Humphries, TJ; Riff, D, 2000) |
| "Rabeprazole, a new proton pump inhibitor, was studied in patients with acid-peptic-related diseases (duodenal ulcer, gastric ulcer, GERD) in three placebo-controlled, double-blind, randomized clinical trials." | 5.08 | Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. ( Bassion, S; Cloud, ML; Enas, N; Humphries, TJ, 1998) |
| "This article presents considerations currently under discussion about the probability of HP participation in the ulcer causation as well as information about Rabeprazole efficiency for anti-helicobacter therapy of non-complicated duodenal ulcer (as a result of 7-day anti-helicobacter therapy, the healing of duodenal bulbs was recorded in 82." | 4.82 | [Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)]. ( Vasil'ev, IuB, 2004) |
| " To evaluate the efficacy of the new PPI rabeprazole, 12 controlled clinical trials were conducted worldwide-three for each indication (erosive or ulcerative GERD healing, long-term GERD healing maintenance, duodenal ulcer healing, and gastric ulcer healing)." | 4.81 | Efficacy of rabeprazole once daily for acid-related disorders. ( Bardhan, KD; Barth, J; Lanza, F; Niecestro, R; Perdomo, C, 2001) |
| " In 8-week studies, among patients with gastro-oesophageal reflux disease (GORD), rabeprazole 20 mg/day or 10mg twice daily was as effective as omeprazole and superior to ranitidine in the healing of GORD." | 4.81 | Rabeprazole: an update of its use in acid-related disorders. ( Carswell, CI; Goa, KL, 2001) |
| " Healing rates for rabeprazole were equivalent to omeprazole in all indications, and superior (GORD healing and duodenal ulcer healing) or equivalent (gastric ulcer healing) to the histamine 2-receptor antagonist ranitidine." | 4.80 | The benefit/risk profile of rabeprazole, a new proton-pump inhibitor. ( Barth, J; Johnson, D; Jokubaitis, L; Perdomo, C, 2000) |
| " pylori infected patients with gastric ulcer and duodenal ulcer completed the triple therapy with 10 mg of rabeprazole b." | 3.72 | Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype. ( Bae, JS; Jung, HS; Kim, HJ; Lee, JK; Lee, SB; Park, SJ; Park, SM; Ryu, JK, 2003) |
| "To conduct a randomised, double-blind, triple-dummy, active-controlled, multicentre trial, named the PLANETARIUM study, to assess the efficacy, dose-response relationship and safety of rabeprazole for peptic ulcer recurrence in Japanese patients on long-term LDA therapy." | 2.79 | Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. ( Arakawa, T; Fujimoto, K; Fujishiro, M; Higuchi, K; Iwakiri, R; Kato, M; Kinoshita, Y; Nakagawa, H; Ogawa, H; Okada, Y; Sanomura, M; Sugisaki, N; Takeuchi, T; Watanabe, T; Yamauchi, M, 2014) |
| "pantoprazole was 6." | 2.74 | Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer. ( Gulzar, GM; Javid, G; Khan, BA; Khan, MA; Shah, AH; Sodhi, JS; U-Saif, R; Yatoo, GN; Zargar, SA, 2009) |
| "Rabeprazole is a new proton pump inhibitor with more potent acid suppressive and anti-Helicobacter effects." | 2.70 | Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. ( Fung, FM; Hu, WH; Hui, CK; Hung, WK; Lai, KC; Lam, SK; Lau, P; Li, KF; Szeto, ML; Tong, TS; Wong, BC; Wong, WM; Yee, YK; Yip, AW; Yuen, MF, 2001) |
| "Group 1 comprised 47 patients with GERD and group 2 49 patients with gastric and duodenal UD." | 1.35 | [Combined therapy of acid-dependent gastrointestinal disorders with the use of antacidic drug Relcer]. ( Andreev, NG; Beliantseva, EV; Golubev, NN; Maev, IV; Odintsova, AN; Samsonov, AA, 2009) |
| ") occurring after the start of rabeprazole treatment were handled as adverse events." | 1.35 | Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan. ( Mizokami, Y, 2009) |
| "Rabeprazole has also been shown to have a more consistent suppression of acid, including at night." | 1.31 | Optimizing acid-suppression therapy. ( Barnett, JL; Robinson, M, 2001) |
| "Rabeprazole has a favourable profile with rapid action and good safety." | 1.31 | [Pharma-clinics medication of the month. Rabeprazole (Pariet)]. ( Louis, E, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (13.73) | 18.2507 |
| 2000's | 36 (70.59) | 29.6817 |
| 2010's | 7 (13.73) | 24.3611 |
| 2020's | 1 (1.96) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, H | 1 |
| Pan, X | 1 |
| Zhang, L | 1 |
| Sun, H | 1 |
| Fan, H | 1 |
| Pan, Z | 1 |
| Huang, C | 1 |
| Shi, Z | 1 |
| Ding, J | 1 |
| Wang, Q | 1 |
| Du, Y | 1 |
| Lyu, N | 1 |
| Li, Z | 1 |
| Fan, L | 1 |
| Xianghong, Q | 1 |
| Ling, W | 1 |
| Ying, H | 1 |
| Jielai, X | 1 |
| Haitang, H | 1 |
| Iwakiri, R | 2 |
| Higuchi, K | 1 |
| Kato, M | 1 |
| Fujishiro, M | 1 |
| Kinoshita, Y | 2 |
| Watanabe, T | 1 |
| Takeuchi, T | 1 |
| Yamauchi, M | 1 |
| Sanomura, M | 1 |
| Nakagawa, H | 1 |
| Sugisaki, N | 1 |
| Okada, Y | 1 |
| Ogawa, H | 1 |
| Arakawa, T | 1 |
| Fujimoto, K | 2 |
| Xie, Y | 1 |
| Zhu, Y | 1 |
| Zhou, H | 1 |
| Lu, ZF | 1 |
| Yang, Z | 1 |
| Shu, X | 1 |
| Guo, XB | 1 |
| Fan, HZ | 1 |
| Tang, JH | 1 |
| Zeng, XP | 1 |
| Wen, JB | 1 |
| Li, XQ | 1 |
| He, XX | 1 |
| Ma, JH | 1 |
| Liu, DS | 1 |
| Huang, CB | 1 |
| Xu, NJ | 1 |
| Wang, NR | 1 |
| Lu, NH | 1 |
| Howden, CW | 1 |
| Lee, HJ | 1 |
| Kim, JI | 3 |
| Lee, JS | 2 |
| Jun, EJ | 1 |
| Oh, JH | 1 |
| Cheung, DY | 3 |
| Chung, WC | 1 |
| Kim, BW | 1 |
| Kim, SS | 1 |
| Li, Y | 1 |
| Wang, XY | 1 |
| Shen, SR | 1 |
| Shin, EK | 1 |
| Moon, W | 1 |
| Park, SJ | 2 |
| Park, MI | 1 |
| Kim, KJ | 1 |
| Kwon, JH | 1 |
| Pellicano, R | 1 |
| Tan, VP | 1 |
| Wong, BC | 2 |
| Javid, G | 1 |
| Zargar, SA | 1 |
| U-Saif, R | 1 |
| Khan, BA | 1 |
| Yatoo, GN | 1 |
| Shah, AH | 1 |
| Gulzar, GM | 1 |
| Sodhi, JS | 1 |
| Khan, MA | 1 |
| Maev, IV | 1 |
| Samsonov, AA | 1 |
| Beliantseva, EV | 1 |
| Golubev, NN | 1 |
| Odintsova, AN | 1 |
| Andreev, NG | 1 |
| Mizokami, Y | 1 |
| Choi, HS | 1 |
| Chun, HJ | 1 |
| Park, SH | 3 |
| Keum, B | 1 |
| Seo, YS | 1 |
| Kim, YS | 1 |
| Jeen, YT | 1 |
| Um, SH | 1 |
| Lee, HS | 1 |
| Kim, CD | 1 |
| Ryu, HS | 1 |
| Murakami, K | 2 |
| Sato, R | 2 |
| Okimoto, T | 2 |
| Nasu, M | 2 |
| Fujioka, T | 2 |
| Kodama, M | 2 |
| Kagawa, J | 2 |
| Sato, S | 1 |
| Abe, H | 1 |
| Arita, T | 1 |
| Lin, S | 1 |
| Catalano, F | 1 |
| Terminella, C | 1 |
| Branciforte, G | 1 |
| Bentivegna, C | 1 |
| Brogna, A | 1 |
| Scalia, A | 1 |
| Osipenko, MF | 1 |
| Pankova, LIu | 1 |
| Bikbulatova, EA | 1 |
| Hassan, C | 1 |
| De Francesco, V | 1 |
| Zullo, A | 1 |
| Scaccianoce, G | 1 |
| Piglionica, D | 1 |
| Ierardi, E | 1 |
| Panella, C | 1 |
| Morini, S | 1 |
| Wang, H | 1 |
| Nie, YQ | 1 |
| Dai, SJ | 1 |
| She, QZ | 1 |
| Li, YY | 1 |
| Lee, SB | 1 |
| Ryu, JK | 1 |
| Lee, JK | 1 |
| Kim, HJ | 1 |
| Bae, JS | 1 |
| Jung, HS | 1 |
| Park, SM | 1 |
| Kornienko, EA | 1 |
| Klochko, OG | 1 |
| Vasil'ev, IuB | 1 |
| Chang, FY | 1 |
| Chen, CY | 1 |
| Lu, CL | 1 |
| Luo, JC | 1 |
| Lu, RH | 1 |
| Lee, SD | 1 |
| Vasil'ev, IuV | 1 |
| Nikol'skaia, KA | 1 |
| Cho, SH | 2 |
| Han, JY | 2 |
| Kim, JK | 2 |
| Han, SW | 1 |
| Choi, KY | 1 |
| Chung, IS | 1 |
| Sung, HY | 1 |
| Park, YB | 1 |
| Takimoto, T | 1 |
| Ido, K | 1 |
| Taniguchi, Y | 1 |
| Satoh, K | 1 |
| Saifuku, K | 1 |
| Kihira, K | 1 |
| Yoshida, Y | 1 |
| Kimura, K | 1 |
| Cloud, ML | 1 |
| Enas, N | 1 |
| Humphries, TJ | 3 |
| Bassion, S | 1 |
| Dekkers, CP | 1 |
| Beker, JA | 1 |
| Thjodleifsson, B | 1 |
| Gabryelewicz, A | 1 |
| Bell, NE | 1 |
| Miller, JL | 1 |
| Breiter, JR | 1 |
| Riff, D | 1 |
| Johnson, D | 1 |
| Perdomo, C | 2 |
| Barth, J | 2 |
| Jokubaitis, L | 1 |
| Thomson, AB | 1 |
| Lanza, F | 1 |
| Bardhan, KD | 1 |
| Niecestro, R | 1 |
| Bardou, M | 1 |
| Rakov, AL | 1 |
| Makarov, IuS | 1 |
| Gorbakov, VV | 1 |
| Mironenko, DA | 1 |
| Golochalova, TV | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 1 |
| Barnett, JL | 1 |
| Robinson, M | 1 |
| Wong, WM | 1 |
| Yee, YK | 1 |
| Hung, WK | 1 |
| Yip, AW | 1 |
| Szeto, ML | 1 |
| Li, KF | 1 |
| Lau, P | 1 |
| Fung, FM | 1 |
| Tong, TS | 1 |
| Lai, KC | 1 |
| Hu, WH | 1 |
| Yuen, MF | 1 |
| Hui, CK | 1 |
| Lam, SK | 1 |
| Starostin, BD | 1 |
| Carswell, CI | 1 |
| Goa, KL | 1 |
| Suzuki, M | 1 |
| Suzuki, H | 1 |
| Kitahora, T | 1 |
| Miyazawa, M | 1 |
| Nagahashi, S | 1 |
| Suzuki, K | 1 |
| Ishii, H | 1 |
| Louis, E | 1 |
| Kulidzhanov, AIu | 1 |
| Usik, SF | 1 |
| Osadchuk, MA | 1 |
| Kvetnoĭ, IM | 1 |
| Kheĭlyk, AI | 1 |
| Sato, H | 1 |
| Abe, K | 1 |
| Oshima, N | 1 |
| Kawashima, K | 1 |
| Hamamoto, N | 1 |
| Moritani, M | 1 |
| Mak, R | 1 |
| Ishihara, S | 1 |
| Adachi, K | 1 |
| Kawauchi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori[NCT01922765] | Phase 4 | 540 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for rabeprazole and Curling Ulcer
| Article | Year |
|---|---|
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
[Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Female; | 2004 |
The benefit/risk profile of rabeprazole, a new proton-pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Controlled Clinical Trials as Topic; Duoden | 2000 |
Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Duode | 2000 |
Efficacy of rabeprazole once daily for acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Benzimidazole | 2001 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 2001 |
Rabeprazole: an update of its use in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2001 |
26 trials available for rabeprazole and Curling Ulcer
| Article | Year |
|---|---|
Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study.
Topics: Amoxicillin; Anti-Ulcer Agents; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Duodenal Ulcer; | 2022 |
Ilaprazole Compared With Rabeprazole in the Treatment of Duodenal Ulcer: A Randomized, Double-blind, Active-controlled, Multicenter Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Dose-Response Relationship, Drug; | 2019 |
Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Double-Blind Method; Duodenal Ulcer; Female; Fibrinolytic Agents; | 2014 |
Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; China; Drug Administration Schedule; Drug Therapy, Combin | 2014 |
Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combina | 2015 |
[Efficacy of 4 kinds of triple strategy for Helicobacter pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 2008 |
Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Drug Administratio | 2009 |
Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alkylating Agents; Amoxicillin; Anti-Bacterial Agents; Anti | 2012 |
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
[The short term effect of rabeprazol versus omeprazole on symptom relief of duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzimidazoles; Double-Blind Metho | 2002 |
Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clar | 2002 |
Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Antacids; Anti-Ulcer Agents; Benz | 2003 |
[The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Aryl Hydrocarbo | 2003 |
[Comparative efficacy of proton pump inhibitors in children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; | 2003 |
Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2005 |
Oral proton pump inhibitors are as effective as endoscopic treatment for bleeding peptic ulcer: a prospective, randomized, controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Duodenal Ulcer; Endoscop | 2007 |
Efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 1995 |
Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Dose-Respo | 1998 |
Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blin | 1999 |
Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2000 |
[Comparative antisecretory activity of famotidine, omeprazole, and rabeprazole (pariet) in ulcer disease based on daily pH-monitoring].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; F | 2001 |
Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2001 |
[Modern means of anti-Helicobacter therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti | 2001 |
Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Biopsy; | 2002 |
[Regeneration of the gastric epitheliocytes during treatment of duodenal ulcer with pariet].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Apoptosis; Benzimidazoles; Duodenal Ulce | 2002 |
17 other studies available for rabeprazole and Curling Ulcer
| Article | Year |
|---|---|
PPI vs. teprenone in preventing recurrence of ulcers during low-dose aspirin - authors' reply.
Topics: Anti-Ulcer Agents; Aspirin; Duodenal Ulcer; Female; Fibrinolytic Agents; Humans; Male; Rabeprazole; | 2014 |
PPI vs. teprenone in preventing recurrence of ulcers during low-dose aspirin.
Topics: Anti-Ulcer Agents; Aspirin; Duodenal Ulcer; Female; Fibrinolytic Agents; Humans; Male; Rabeprazole; | 2014 |
Congenital absence of the splenic artery and splenic vein accompanied with a duodenal ulcer and deformity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Duodenum; Female; Humans | 2009 |
Management of acute peptic ulcers: how ethnicity, different proton pump inhibitors and mechanism of delivery alter the equation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Asian People; Drug Administration Sch | 2009 |
[Combined therapy of acid-dependent gastrointestinal disorders with the use of antacidic drug Relcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; A | 2009 |
Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclo | 2009 |
[Medico-economic efficacy of eradication schemes in helicobacter infections in patients with duodenal ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Benzimidazoles; Cost of Illne | 2003 |
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
[Results of the treatment of duodenal ulcer associated with Helicobacter pylori and combined with gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 2005 |
The papilla of Vater just below the pylorus presenting as recurrent duodenal ulcer bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Bile; Bile Ducts; Duodenal Ulcer; | 2007 |
[Proton-pump inhibitor Rabeprazole: faster acid- and symptom-control].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 1998 |
Rabeprazole is latest entrant in proton-pump-inhibitor class.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 1999 |
Rabeprazole sodium.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 1999 |
Rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adenosine Triphosphatases; Anti-Ulcer Agent | 1999 |
Optimizing acid-suppression therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Duode | 2001 |
[Pharma-clinics medication of the month. Rabeprazole (Pariet)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clinical Trials as Topic; Duodenal Ulcer; E | 2002 |
Primary hyperparathyroidism with duodenal ulcer and H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Aged; Anti-Ulcer Agents; Benzimidazoles; Duodenal | 2002 |